Immunovaccine (IMV: CA) Announces Closing of $10 Million Bought Deal Offering

Spotlight Companies  |

ImmunoVaccine Inc. (IMV: CA) has closed the previously announced bought deal public offering of common shares of the corporation, raising gross proceeds of approximately $10-million.

"Following the successful closing of this deal, ImmunoVaccine is well financed to plan for a phase 1 clinical trial aimed at expanding the application of DPX-Survivac (its lead cancer vaccine) across multiple indications," said Frederic Ors, ImmunoVaccine's chief executive officer. "The target of DPX-Survivac, survivin, is associated with more than 20 types of hematological and solid cancers. With this association, and its other unique properties, we have only just begun to scratch the surface of DPX-Survivac's potential within our growing pipeline. We are excited to continue our aggressive pursuit of bringing groundbreaking immunotherapies to the many millions of underserved people living with difficult-to-treat cancers."

The offering was conducted through a syndicate of underwriters led by Echelon Wealth Partners Inc. and National Bank Financial Inc., and including Mackie Research Capital Corp. As part of the offering, ImmunoVaccine has granted the underwriters an overallotment option to purchase up to an additional 1,153,846 common shares at a price of $1.30 per common share, exercisable until July 21, 2017, for additional gross proceeds of up to $1.5-million.

The corporation intends to use the net proceeds of the offering for the research and development and clinical advancement of its cancer and infectious disease vaccine candidates, and for working capital and general corporate purposes.

Certain insiders of the corporation participated in the offering and purchased an aggregate of 874,630 common shares. Participation of insiders of the corporation in the offering constitutes a related-party transaction as defined under Multilateral Instrument 61-101, but is exempt from the formal valuation and minority shareholder approval requirements of MI 61-101, as neither the fair market value of securities being issued to insiders nor the consideration being paid by insiders will exceed 25 per cent of the corporation's market capitalization. None of the corporation's directors have expressed any contrary views or disagreements with respect to the foregoing. The corporation did not file a material change report 21 days prior to the closing of the offering as the details of the participation of the insiders of the corporation had not been confirmed at that time.

About ImmunoVaccine Inc.

ImmunoVaccine is a clinical-stage biopharmaceutical company dedicated to making immunotherapy more effective, more broadly applicable and more widely available to people facing cancer and infectious diseases. ImmunoVaccine develops T-cell-activating cancer immunotherapies and infectious disease vaccines based on DepoVax, the corporation's patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. ImmunoVaccine has advanced two T cell activation therapies for cancer through phase 1 human clinical trials and is currently conducting a phase 1b study with Incyte Corp. and a phase 2 study with Merck assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The corporation is also exploring additional applications of DepoVax, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus, which has recently completed a phase 1 clinical trial. ImmunoVaccine also has continuing clinical projects to assess the potential of DepoVax to address malaria and the Zika virus.

In the interest of full disclosure, we call the reader's attention to the fact that Equities.com, Inc. is compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way be considered as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker dealer, investment advisor, financial analyst, investment banker or other investment professional. We are a publisher of original and third party news and information. All profiles are based on information that is available to the public. The information contained herein should not be considered to be complete and is not guaranteed by Equities.com to be free from misstatement or errors. The views expressed are our own and not intended to be the basis for any investment decision. Readers are reminded to do their own due diligence when researching any companies mentioned on this website. Always bear in mind that investing in early-stage companies is risky and you are encouraged to only invest an amount that you can afford to lose completely without any change in your lifestyle. Equities has been compensated with cash, common shares and/or warrants for market awareness services provided.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Comments